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An in vitro assessment of
liposomal topotecan simulating
metronomic chemotherapy in
combination with radiation in
tumor-endothelial spheroids
Amar Jyoti1, Kyle D. Fugit1, Pallavi Sethi1, Ronald C. McGarry2, Bradley D. Anderson1 &
Meenakshi Upreti1
Low dose metronomic chemotherapy (LDMC) refers to prolonged administration of low dose
chemotherapy designed to minimize toxicity and target the tumor endothelium, causing tumor
growth inhibition. Topotecan (TPT) when administered at its maximum tolerated dose (MTD) is often
associated with systemic hematological toxicities. Liposomal encapsulation of TPT enhances efficacy
by shielding it from systemic clearance, allowing greater uptake and extended tissue exposure
in tumors. Extended release of TPT from liposomal formulations also has the potential to mimic
metronomic therapies with fewer treatments. Here we investigate potential toxicities of equivalent
doses of free and actively loaded liposomal TPT (LTPT) and compare them to a fractionated low
dose regimen of free TPT in tumor-endothelial spheroids (TES) with/without radiation exposure
for a prolonged period of 10 days. Using confocal microscopy, TPT fluorescence was monitored to
determine the accumulation of drug within TES. These studies showed TES, being more reflective
of the in vivo tumor microenvironment, were more sensitive to LTPT in comparison to free TPT
with radiation. More importantly, the response of TES to low-dose metronomic TPT with radiation
was comparable to similar treatment with LTPT. This TES study suggests nanoparticle formulations
designed for extended release of drug can simulate LDMC in vivo.

Traditional chemotherapeutic regimens incorporate the maximum tolerated dose (MTD)1 resulting in
systemic toxicity. These toxicities mandate rest periods between cycles of therapy and result in re-growth
of drug-resistant tumor cells and growth of more malignant tumors with no therapeutic response2. Low
dose metronomic chemotherapy (LDMC) designed to minimize toxicity, functions by targeting the
tumor microenvironment, particularly the endothelial cells, by frequent, fractionated doses of MTD. The
potential need for frequent administrations has not allowed LDMC to advance beyond investigational
applications. Topotecan (TPT), a water soluble camptothecin with topoisomerase I inhibitory activity
when administered at its maximum tolerated dose (MTD) is often associated with systemic hematological toxicities. Metronomic oral TPT has been reported to have beneficial outcomes in clinical trials3,4
and preclinical tumor models5,6 of various cancer types. Liposomal encapsulation of TPT enhances its
efficacy by shielding it from systemic clearance, allowing greater uptake and extended tissue exposure in
solid tumors7,8. Extended release of TPT from liposomal formulations also has the potential to mimic
metronomic therapies with fewer treatments. Endothelial cells in tumors are typically more sensitive than
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other tumor cells to prolonged LDMC9. Targeting these endothelial cells blocks tumor angiogenesis and
eventually inhibits tumor growth10,11. However, similar to other anticancer therapies, inherent resistance
to LDMC is also frequent12. Existing pre-clinical tumor cell models have yet to incorporate the variables
of angiogenesis and intercellular heterogeneity of the tumor microenvironment. Furthermore, evaluating
LDMC before extending it to preclinical animal models and clinical settings has also been difficult due
to the above mentioned variables13.
The inadequacies of the tumor microenvironment in most in vitro tumor cell models has also made
the design of drug delivery systems with optimal drug release rates challenging. The chronically aberrant vascular pathophysiology of developing tumors results in a leaky vasculature and poor lymphatic
drainage14 that allows nanosized drug carriers like liposomes to preferentially accumulate. The enhanced
permeability and retention (EPR) effect can result in 10–50 fold higher concentration of nanoparticles
in tumors than in normal tissue15. Furthermore, sustained release of active drug from these nanoformulations simulates the action of metronomic therapy16. However, accumulation of drug-loaded liposomes
in tumors as a consequence of the EPR effect may not lead to optimal free drug concentrations at the
tumor site, and thus may not be a sufficient indicator of therapeutic efficacy17. Traditional 2D monolayer
cell culture systems do not exemplify the complexity of the tumor and its microenvironment and are also
not optimal for assessing nanoparticle efficacy18. Therefore, an in vitro tumor model that is amenable to
monitoring nanoparticle penetration, drug release, and their subsequent effects on tumor cell viability
and/or tumor growth is needed. The 3D system of tumor and endothelial cells co-cultured in ‘hanging drops’ recreates aspects of the tumor microenvironment, offering a simple yet potentially powerful
in vitro tumor model to study therapeutic response. These avascular multicellular TES recreate the gradient of hypoxia, pH and interstitial pressure that results in the inner necrotic and the outer proliferating
layer of cells similar to solid tumors in vivo19,20. The co-culture of different cell types in 3D also facilitates
the inter-cellular crosstalk leading to the formation of an extracellular matrix known to influence the
therapeutic response in cancer21. Liposomal formulations of TPT enhance the anticancer efficacy of TPT
and significantly reduce tumor growth7,8 but reasons behind this outcome are not fully understood. In
the current study, a TES model of triple negative breast cancer (TNBC) was used to investigate whether
the extended release and drug penetration from liposomal TPT provided similar cytotoxicity as metronomic dosing.
Radiation alters the adjacent tumor microenvironment often with consequences for cancer cells
beyond the direct effects of the radiation itself 22. Radiation therapy with concomitant or delayed chemotherapy is given to almost 70% of the patients with cancer. TPT has also been shown to induce radiosensitization upon prior or concurrent treatment with radiation23. Therefore, this study investigates the
combined effect of a clinically relevant dose of radiation (3 Gy) in conjunction with free or liposomal on
avascular tumor-endothelial spheroids over an extended period of 10 days.

Results

Extended release kinetics of LTPT in physiological buffer and culture medium. Simulating

metronomic dosing requires sustained release of TPT from liposomes under study conditions. Using a
spectroscopic method developed in previous work to monitor the release kinetics of LTPT in aqueous
buffer and biological fluids24, TPT release was monitored in cell culture medium to determine if LTPT
formulations provided sustained release in TES media. Release kinetics of three different LTPT suspensions (11, 17 and 23 μ M total suspension TPT) in TES media are shown in Fig. 1 and were compared
to release from LTPT (12 μ M total suspension TPT) in pH 7.4 PBS. While slightly greater in cell culture
media than in PBS, TPT release was still sustained over the 31 hr period release was monitored. This
time frame is relevant when considering TESs treated with LTPT were washed after 24 hr of exposure
to the formulation.

Higher intrinsic sensitivity of endothelial cells to TPT alone and in combination with radiation
than tumor cells. Cellular viability was determined by MTT assay in monolayer cell cultures of 4T1

mammary breast carcinoma and 2H11 endothelial cell lines treated with increasing concentrations of
TPT. Comparing Fig. 2A,B clearly demonstrates that endothelial cells are more sensitive to TPT treatment. The half maximal inhibitory concentrations (IC50) of TPT were 130 nM for endothelial cells and
630 nM for tumor cells. Combined treatment of TPT in conjunction with radiation further sensitized
both the tumor and endothelial cells in the 72 hour MTT assay. An approximate 10-fold decrease was
evident in the values of the IC50 of the tumor cells from 630 nM to 75 nM and endothelial cells from 130
to 17 nM, respectively, when TPT treatment was combined with 3 Gy of radiation after 6 hours.
Ionizing radiation triggers a myriad of responses in cells, including apoptosis, necrosis, stress-induced
premature senescence (SIPS) and autophagy. Most of these responses result in loss of colony-forming
ability that may be assessed in the clonogenic survival assay25. Clonogenic studies to understand the
effects of TPT and radiation exposure of 3 Gy in tumor and endothelial cell lines further indicated that
TPT concentrations at one-half and one-fourth of the IC50 were more effective in inhibiting survival of
both cell types (Fig. 2C,D).

Tumor-endothelial cell spheroids (TES): an in vitro model to assess drug penetration and
accumulation. Tumors in vivo are not merely aggregates of cancer cells but are representative of
Scientific Reports | 5:15236 | DOI: 10.1038/srep15236

2

www.nature.com/scientificreports/

Figure 1. Extravesicular TPT concentrations versus time in LTPT suspensions at various dilutions in
PBS or culture media at pH 7.4 and 37 °C. Release profile of LTPT formulations in PBS buffer and spheroid
culture media at pH 7.4 and 37 °C. Graph represents the extravesicular TPT concentration calculated over
time in the TES culture media and PBS buffer. The extravesicular TPT was quantified by monitoring TPT
fluorescence at ex. and em. wavelengths of 410 and 550 nm, respectively. The lines are trendlines for the four
different release experiments.

Figure 2. Endothelial cells are more sensitive to low concentrations of TPT alone and in combination
with radiation in comparison to tumor cells. Effect of TPT treatment on the viability of tumor (A) and
endothelial cells (B) was assessed with or without radiation (3 Gy) exposure in a 72h MTT assay. IC50 values
obtained from the MTT assay indicate that X-ray irradiation post TPT treatment considerably decreases
the viability of both tumor and endothelial cells. Long term survival studies further validate the impact of
radiation (3y) on tumor and endothelial cell colony formation with and without TPT at ½ or ¼ of the IC50
concentrations. For the survival assay, cells were exposed to drug and/or radiation and then grown in drugfree medium for 10–14 days. Colonies (> 50 cells) were stained with crystal violet and counted (Materials
and Methods). Data represent means ±  SD (n =  3). Significant changes were recorded as **p <  0.01;
*p <  0.05.

structurally and functionally deregulated organs with a 3D tissue architecture contributed by multiple cell types and the extracellular matrix26,27. Gravity-enforced self-assembly generates multicellular
scaffold-free aggregates in a self-contained microenvironment28. The penetration of free TPT was assessed
Scientific Reports | 5:15236 | DOI: 10.1038/srep15236
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Figure 3. Tissue-like integrated morphology and development of extracellular matrix prevents
penetration of TPT in the TES. (A) Tumor cell only and tumor-endothelial cell (TES) spheroids were
incubated in 2.5 μ M TPT for 6 hours and extent of uptake was assessed using fluorescent confocal imaging.
Efficient uptake of TPT imaged at excitation wavelength 410 nm was observed in tumor cell spheroids.
There was minimal penetration of the fluorescent TPT (green). Scanning electron micrographs (B), histology
(C) and immunostaining for ECM proteins (D) like collagen and fibronectin indicate the compactness as
well as the presence of ECM in the TES.

at excitation wavelength of 410 nm in tumor cell only and tumor-endothelial cell spheroids (TES) incubated in 2.5 μ M TPT for 6 hours by confocal fluorescence microscopy. The drug uptake within 6 hours
of incubation was noticeably higher in the tumor cell only spheroids in comparison to tumor-endothelial
cell spheroids (TES) (Fig. 3A). Scanning electron microscopy and H & E staining revealed that while
tumor cells remain as aggregates and fail to form intact spheroids, the tumor and endothelial cells in the
TES developed an integrated and compact architecture with indications of ECM formation (Fig. 3B,C).
Immunohistochemical (IHC) studies indicated that the presence of both tumor and endothelial cells in
3-dimensions causes the production of extracellular matrix proteins like fibronectin and collagen. These
factors may be responsible for the integrated tissue-like morphology and greatly limited penetration of
TPT (Fig. 3D). The presence of extracellular matrix (ECM) has been reported to affect the penetration
of therapeutic agents in solid tumors29 as observed in the present study. The tumor cell only spheroids
exist as unattached cell aggregates and are either washed out during the IHC procedures or have minimal
expression of ECM proteins (data not shown).

Scientific Reports | 5:15236 | DOI: 10.1038/srep15236
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Figure 4. Liposomal TPT formulation facilitates penetration of TPT in TES over an extended period
of 10 days. Comparisons of intra-spheroidal TPT uptake in TES when incubated in the presence of either
free or liposomally entrapped TPT for 24 hours with and without radiation exposure of 3 Gy at day 10
post-treatment. (A) Confocal TES images were partitioned into 5 concentric zones for quantification of TPT
accumulation (Zones (1–5). (B) Representative confocal images after treatment of 24 optical slices (i.e. each
z-stack image) taken every 5 μ m from the center to bottom of the intact TES. The top left image in each tile
is a 3D reconstruction of the stack of 24 confocal optical sections. (C) Quantification of TPT accumulation
based on the integrated TPT fluorescence intensity (integrated intensity normalized to surface area in each
zone to avoid bias) in each zone of the TES after treatment with liposomal TPT. (D) Heat map of fluorescent
confocal images showing the intracellular accumulation of TPT across the y and z-axis of TES. Each image
represents averages of fluorescence intensity of 4 TES within the same treatment group.

Higher TES accumulation and penetration of TPT from liposomal formulations. The TES
were incubated in 5 μ M of free or LTPT with and without radiation exposure (3 Gy) for 24 hours. The
media was replaced and the spheroids were assessed for accumulation and penetration of TPT at day 10.
Sustained release of drug from liposomes and changes caused by radiation are expected to occur over
a period of time in vivo. Therefore, drug accumulation and cytotoxicity in TES was assessed at 10 days
post-treatment for optimal results. Maximum intensity projections of a stack of 24 confocal images at a
5 μ m step size of each TES were portioned into 5 concentric zones as shown in Fig. 4A. The integrated
intensity normalized to surface area of each respective zone in every treatment group was represented in
Fig. 4C. The quantification of TPT accumulation based on the fluorescence intensity in each zone of the
TES 10 days after treatment indicates significantly higher accumulation in zone-1 and zone -2 of TES
incubated in LTPT following radiation exposure (Fig. 4C). Figure 4B is a representative image showing
a confocal image of a TES in tile mode, with accumulation and penetration of the drug in the 24 optical
sections at different z-levels. Heat maps depicting the distribution of TPT within the TES in different
treatment groups further indicate that the drug penetration was more efficient in TES incubated in LTPT
and exposed to a 3 Gy dose of radiation (see Fig. 4D). Absence of the outer zones (3, 4 and 5) reflects a
Scientific Reports | 5:15236 | DOI: 10.1038/srep15236
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Figure 5. Enhanced cytotoxicity in TES upon combined treatment with a low concentration of
liposomal TPT (LTPT) and radiation. (A) Representative confocal images of GFP expressing tumor cells
and PI uptake elucidating the effect of free and entrapped TPT treatment (250 nM) with and without
radiation (3 Gy). Each treatment was expected to reduce the overall fluorescence of GFP expressing 4T1
tumor cells, increase the accumulation of the PI stain and decrease the size of TES. These effects are
indicative of the level of cytotoxicity conferred by each treatment. Increase in PI staining, decrease in
spheroid size and GFP expression were observed in TES treated with LTPT followed by radiation exposure,
indicating higher cytotoxicity. (B) Spheroid size and the ratio of PI/GFP intensity were evaluated using
ImageJ software. (n =  12 TES for spheroid size per treatment and n =  4 TES for PI/GFP ratio) **P <  0.01.

decrease in TES size. Penetration of TPT to the inner layers of the TES is indicative of the higher level
of cytotoxicity resulting from the combined treatment of LTPT and radiation in comparison to the other
treatment groups.
Free and liposomal formulations of TPT at concentrations of 5 μ M were also prepared in the pH
7.4 culture medium used to grow the TES. Six hours later, treated TES were imaged by confocal florescence microscopy at an excitation wavelength of 410 nm. The fluorescence intensity of the culture
medium with liposomally entrapped TPT (LTPT) was exceptionally low in comparison to free TPT
(Supplementary Figure. 1). Similar images were obtained at 24 hours, the time point when the TES
medium was replaced with fresh medium (data not shown). These results, in addition to those in Fig. 4,
suggest that TPT-loaded liposomes accumulate in the TES within 24 hours, followed by extended release
of the drug during the 10 day studies.

Low concentrations of LTPT and radiation enhance TES cytotoxicity when assessed over
a prolonged period of time. The anti-tumor effects of radiation and TPT occur via their impact

on the tumor microenvironment, particularly the endothelial cells30. The response of the tumor/tumor
microenvironment to combined therapy using liposomally-entrapped TPT and radiation was assessed
in 3D co-cultures of tumor and endothelial cells (TES) by incubating at a TPT concentration of 250 nM
followed by exposure to a clinically relevant dose of radiation (3 Gy). The selected TPT concentration
was 2-fold higher than the half maximal inhibitory concentration (IC50) for endothelial cells and 3-fold
less than the IC50 for the tumor cells (Fig. 2). The effect of free and LTPT with and without radiation
(3 Gy) was observed on day 10 by assessing the size, GFP expression of 4T1 tumor cells and extent of
cell damage by Propidium Iodide (PI) staining of TES (Fig. 5A,B).
Scientific Reports | 5:15236 | DOI: 10.1038/srep15236
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PI is a fluorescent nuclear and chromosome counterstain that is impermeant to live cells, making it a
useful indicator of dead cells within a population. The emission maximum for the dye bound to DNA is
617 nm and therefore it fluoresces red31. TES subjected to radiation exposure (3 Gy) alone underwent a
decrease in size at day 10 with a moderate increase in PI staining. While staining with PI was significant
in TES that were incubated in LTPT with and without radiation exposure (3 Gy) the combined effects of
a decrease in size and cell damage as observed by PI staining were significantly higher in TES that were
subject to incubation with LTPT in conjunction with radiation (Fig. 5A). High throughput evaluations
of spheroid size and ImageJ-based determinations of decrease in the fluorescence intensity of green fluorescent (GFP) expressing 4T1 tumor cells (green) and increase of PI staining in the TES further validate
the enhanced cytotoxicity induced by LTPT in conjunction with radiation (Fig. 5B).

Extended release of TPT from liposomes mimics the low dose metronomic dosing effect in
TES. Metronomic chemotherapy targets the tumor microenvironment, particularly the endothelial

cells which are more sensitive to lower and sustained doses of drugs than the tumor cells. Inhibiting
tumor endothelial cells disrupts the normal interaction of tumor cells with their microenvironment,
making it difficult for the tumor cells to survive and eventually the inhibition of tumor growth10. As
shown in the present study and reported earlier, endothelial cell types are more sensitive to TPT than
tumor cell types (Fig. 2 and32). The sustained release of liposomally entrapped TPT was expected to
simulate low dose metronomic chemotherapy. To investigate whether the metronomic dosing effect can
be replicated in vitro, the responses of TES to a single dose of free TPT, liposomally entrapped TPT, and
fractionated low doses of TPT in conjunction with radiation exposure were compared. TES were treated
with free or entrapped TPT (250 nM) followed by radiation exposure after 6 hours. The culture media was
replaced after 24 hours as described earlier for toxicity evaluation. For low dose metronomic treatment,
the single dose of free TPT was fractionated into 3 or 5 doses given every 24 hours. Thus, the treatments
consisted of 83 nM concentrations of free TPT every 24 hours for 3 days (3 fractions, 3 ×  83 nM) or
50 nM concentrations of TPT every 24 hours for 5 days (5 fractions, 5 ×  50 nM) followed by subsequent
replacement with fresh medium 24 hours after each treatment. At day10 the TES were imaged for sizing, drug uptake and cell damage by confocal fluorescence microscopy. Decrease in TES size correlated
with increased accumulation of TPT (green) and enhanced cell damage observed by PI staining (Red).
The treatment results in TES that received fractionated dosing and radiation were comparable to those
treated with the single dose of LTPT followed by radiation exposure (3 Gy) (Fig. 6A). Of the two free TPT
metronomic treatment regimens, the 3 ×  83 nM regimen was more effective than the 5 ×  50 nM regimen
(Fig. 6B). The results further suggest the relevance of an optimal in vitro model for preclinical evaluation
of LDMC. Figure 7 provides a schematic comparing free, liposomal and metronomic dosing regimen of
TPT in conjunction with radiation on TES at 10 days post treatment.

Enhanced cytotoxicity of LTPT with radiation results from differential intracellular phosphoMAPK signaling in the endothelial component of the TES. A semi-quantitative comparison of

the expression of 26 phosphoproteins involved in the stress and apoptotic signaling pathway in response
to free TPT and LTPT at day 10 was performed by probing the Phospho-MAPK antibody arrays with
TES lysates (Fig. 8A). ImageJ analyses of pixel intensities was used to identify the differential expression
of phosphoproteins under different treatment conditions. The heat map generated (Fig. 8B) revealed
a 2–5 fold increase in phosphorylation of JNK and p38 and ERK family of MAP kinases in the TES
treated with LTPT and radiation. JNK and p38 are stress activated MAP kinases which are upregulated in response to camptothecin derivatives like topotecan33,34 and radiation35,36. Sustained activation
of ERK1/2, JNK or p38 plays a crucial role in the regulation of apoptosis, cell cycle progression, growth
and differentiation37,38. JNK and p38 induce apoptosis by phosphorylating pro-apoptotic BAD39 and inactivation of anti-apoptotic Bcl-2 and Bcl-xL proteins40.
Based on the different phosphoprotein expression trends in TES in response to various treatment
conditions, they were grouped into two clusters (Figs 8B and 9). In cluster-1 consisting of 6 phosphoproteins, the three treatment groups including radiation alone and free or LTPT with radiation exhibited a trend of increasing phosphorylation. However, the 8 phosphoproteins in cluster-2 appeared to be
selectively upregulated in TES that were treated with LTPT and radiation (Fig. 9A). Of further interest
was the phosphorylation of p53 at the serine 46 residue in cluster-1. Phosphorylation of the serine 46
residue is critical to triggering the p53 dependent apoptotic signaling cascade found to occur in normal
cell types41. Apoptotic stress resulting in phosphorylation of ERK, p38, and JNK has also been associated
with phosphorylation and stabilization of the p53 tumor suppressor protein42. However, within TES,
only the 2H11 endothelial cells that have a functional p53 that will undergo activation in response to an
apoptotic or stress signal. The 4T1 murine mammary carcinoma cells are p53 null and do not express
the p53 protein43. The Ingenuity pathway analysis (IPA) elucidated that the phosphorylation/activation of
these proteins is associated with p53 (serine 46 residue) phosphorylation and impacts the amplification
of apoptotic signals (Fig. 9B). The data suggests that the metronomic effect of the combined treatment
of liposomal TPT and radiation on endothelial cells may be a possible reason for efficient activation of
ERK, JNK and p38 family of MAP kinases resulting in enhanced toxicity observed at day 10 in the TES.

Scientific Reports | 5:15236 | DOI: 10.1038/srep15236
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Figure 6. A single LTPT treatment results in TES toxicity levels that are comparable to the fractionated
(metronomic) dosing regimen using free TPT in conjunction with radiation. The toxicity of repeated
fractionated dosing was investigated against a single dose of free TPT or LTPT followed by a single exposure
to radiation (3 Gy) in each treatment after the first dose. Fractionated regimens consisting of 3 ×  83 nM
or 5 ×  50 nM TPT treatments with exchanges occurring each 24 hours were given and toxicity to TES was
evaluated at day 10 post-treatment. (A) Fluorescence confocal images indicate greater uptake of PI (red)
and accumulation of TPT (green) in the TES treated with repeated low concentrations of free TPT or the
liposomal formulation in comparison to a single treatment of free TPT at a higher concentration (250 nM).
Representative DIC images with decreases in the size of the TES confirm the associated cytoxicity in these
treatment groups. (B) Quantitative analysis of spheroid size, TPT and PI intensity assessed at day 10 posttreatment for the various treatment groups described indicates that the effect of the liposomal formulation
was comparable to the fractionated dosing of free TPT. This is supported by the lack of significance in
in TPT or PI uptake between LTPT and the metronomic TPT dosing. (n =  12 TES for spheroid size per
treatment and n =  4 TES for PI staining and GFP expression) *P <  0.05; **P <  0.01.

Discussion

The typical treatment options available for TNBC are a combination of therapies such as surgery,
chemotherapy and radiation44. Chemotherapy followed by radiotherapy has been shown to significantly
increase the survival outcomes in TNBC women after mastectomy45. Metronomic oral topotecan alone
or in combination with pazopanib has been shown to prolong survival and reduce metastasis in gastrointestinal and gynecological cancers5,46,47. Its use in LDMC has been limited in other types of cancers due
in part to its short half-life of 3.5 hours in the circulation48 and the need for frequent administration47,49.
Continuous infusion via intravenous administration not being a logical option owing to the patients
inconvenience, has met with limited success and not yet become a standard practice in the clinic50,51.
Efficiently loaded nanoparticles not only stabilize the therapeutic agents and influence the drug’s biodistribution52, but may also facilitate sustained release at the vascularized tumor site53,54. This sustained
release in turn provides low concentration of active drug at the tumor site over a prolonged period of
time, thus simulating the action of localized metronomic therapy in cancer16.
Scientific Reports | 5:15236 | DOI: 10.1038/srep15236

8

www.nature.com/scientificreports/

Figure 7. A schematic representation of free and liposomally entrapped TPT (LTPT) compared to
the metronomic dosing regimen of free TPT studied in TES. Treatment response was determined
by evaluating the changes in fluorescence intensity of TPT uptake, spheroid sizing of DIC (differential
interference contrast) images, and propidium iodide (PI) staining of dead/damaged cells.

Figure 8. Phospho-MAP kinase expression profiling reveals elevated activation of proteins associated
with stress and apoptotic signaling in TES treated with LTPT and radiation in comparison to a similar
concentration of free TPT. (A) The human phosho-MAPK array was utilized to detect upregulation of
several phosphoproteins in the TES spheroids treated with 250 nM LTPT or free TPT followed by radiation
exposure of 3 Gy after 6 hours. TES subject to radiation exposure alone served as a control. Data shown
are from a 60 second exposure of the array blot to x-ray film. (B) The graphs of pixel intensities (cluster
1 and 2) representative of phosphoprotein expression profiles in TES upon treatment with free TPT and
liposomally entrapped nanoformulation (LTPT) combined with radiation exposure.

The rational use of antineoplastic agents in pharmacotherapy requires preclinical studies to model
the pharmacokinetic/pharmacodynamics (PK/PD) for predicting the effect and efficacy of drug dosing
over time. While the alternate paradigm of metronomic therapy is gaining pace when compared to the
traditional paradigm of cytotoxic chemotherapy based on the MTD, there is still no accepted definition
of the ‘metronomic dose’. Majority of the clinical trials administering metronomic therapy have utilized
an arbitrary dose range of 10–33% of the MTD as the representative metronomic dose10,55. Therefore,
to maximize the antitumor response, metronomic approaches have yet to optimize the drug schedule
and dosage. In this respect cost-effective in vitro models, that allow for controlled experimental manipulation, present a valuable predictive tool for optimization of dosing schedules before translation of the
data to animals and clinical trials56. Advancing the efficacy of LDMC not only requires testing capable
of determining the optimal dose but possible interaction of the formulation with other co-administered
treatment modalities12,57. Current initiatives to address the specific issues of right dose, rhythm of drug
administration and co-treatment modalities for LDMC utilize the novel approach of mathematical
Scientific Reports | 5:15236 | DOI: 10.1038/srep15236
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Figure 9. The trend of phophoprotein expression and signaling network. (A) Based on the pixel densities
of the signal in each spot of the array corresponding to the respective phosphorylated protein, they were
grouped in one of the two clusters. (B) Ingenuity pathway analysis shows the interaction of phosphorylated
proteins that are significantly activated in irradiated TES incubated in LTPT for 10 days. Interestingly
activation of these proteins is associated directly or indirectly with the phosphorylation of functional p53
(serine 46 residue) which is expected to be activated in endothelial cells only.

modeling of cancer growth58,59. A mathematical model based on the combined dynamics of the proliferating quiescent and necrotic tumor cells, endothelial cells and other normal cells along with the influence
of the oxygen gradient and angiogenic factors was designed by Andre et. al to reproduce the expected
efficacy of MTD and metronomic schedule for Temozolomide chemotherapy59. The usefulness of such
mathematical models is in their versatility to adapt to several kinds of single or multi-agent therapeutic
strategies. Multicellular tumor spheroids have served as ideal experimental model system for deriving
the mathematical algorithms for cancer growth and associated therapy60–62. The 3D co-culture of tumor
and endothelial cells in this study provides an improved system for the mathematical modeling of tumor
and endothelial cell sensitivity to LDMC and determine the most effective drug/ therapeutic combination
to translate to clinical settings.
In the current study we have developed a cost- effective tumor model for the screening and testing of
metronomic and/or combinatorial therapeutic responses in vitro. The ability of the in vitro TES model to
capture characteristics of the tumor microenvironment and continue to grow for several weeks in culture,
unlike 2D monolayer cultures that need to be passaged in 3–4 days, enables analysis of the gradient of
penetration/accumulation of drugs or nanoparticles over an extended period of time and provides a
more predictive assessment of in vivo response. The 4T1 murine mammary carcinoma cells selected
for co-culturing with the murine 2H11 endothelial cell line in this study exhibit growth and metastasis
spread closely mimicking the human TNBC prognosis63. The 2H11 murine endothelial cell line isolated
from the lymph nodes of adult C3H/He mice64 is very well characterized by the presence of features
typical of normal endothelial cells and those of endothelial cells isolated directly from tumors65. These
studies (Fig. 2) correlate with earlier reports that demonstrate that endothelial cells are more sensitive
than tumor cells to TPT32 and radiation66,67. Recently redefined by Klement and Kamen, LDMC is the
minimum biologically effective dose of a chemotherapeutic agent, which, when given at a continuous
dosing regimen with no prolonged drug-free breaks leads to anti-tumor activity68 The antitumor activity
of LDMC is due to increase in the sensitivity of proliferating endothelial cells in the tumor vasculature
and inhibition of angiogenesis10,69. As demonstrated herein, sustained release of TPT from the liposomal
formulation (LTPT) enhances TPT toxicity to the endothelial cells and provides similar efficacy in the
TES model as metronomic therapy. Combined treatment with a single dose of LTPT and radiation also
enhanced cytotoxicity and cell damage in the TES (Figs 4–7). Furthermore, semi-quantitative molecular
studies using Phosho MAPK antibody arrays indicated that the enhanced TES cytotoxicity resulting
from a combination of incubation with LTPT and radiation exposure is associated with the activation/
phosphorylation of p53 in endothelial cells as shown in Figs 8 and 9.
Efforts to evaluate complex combinations and novel cancer therapies have been challenging and
require more representative yet cost-effective and reproducible in vitro models of human cancer. To
evaluate metronomic therapy and radiation in preclinical in vitro models it is critical to have a more realistic representation of the tumor-endothelial cells, as both metronomic therapy and radiation function
by affecting the tumor microenvironment. Further, the liposomal accumulation and drug release at the
tumor site are extremely important for an understanding of the overall drug efficiency. Traditionally this
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information is obtained from in vivo studies in animal models. In vitro tumor models that can incorporate the principles of pharmacokinetics and pharmacodynamics (PK/PD) nanoparticle drug delivery to
optimize therapeutic response may be considered the method of choice for optimizing the drug design
prior to initiating expensive and resource-intensive experiments in animals56,70,71. The current studies
demonstrate that a 3D TES model provides such representation of the tumor microenvironment by illustrating enhanced penetration and efficacy of liposomal formulations of TPT alone and in conjunction
with a clinically-relevant dose of radiation.

Materials and Methods

Materials. Topotecan hydrochloride was purchased from AK Scientific (Union City, CA). Powders of

1, 2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC), > 99%, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000] (ammonium salt) (m-PEG DSPE), > 99%
purity, were purchased from Avanti Polar Lipids (Alabaster, AL). Nuclepore polycarbonate membranes
(0.1 μ m), Dowex 50WX8-200 resin in the H+ form, Sephadex G-25 PD-10 columns, solvents, and
buffer salts were purchased from Fisher Scientific (Florence, KY). All solvents were HPLC grade. MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was purchased from Sigma-Aldrich (St.
Louis, MO), and cell culture media was obtained from GIBCO Life Technologies (Carlsbad, CA).

®

®

®

Actively-loaded Liposomal TPT Formulations. Large unilamellar liposomes containing 0.3 M

ammonium besylate solutions were prepared as previously reported72,73. Briefly, DSPC and m-PEG-DSPE
(95:5 molar ratio) were dissolved in chloroform. A thin lipid film was generated after evaporating CHCl3
under N2 and fully dried under vacuum at 35 °C for 6 hours. Dried films were hydrated with 0.3 M
ammonium besylate solutions made via ion exchange using Dowex 50WX8–200 as reported previously24. The resulting suspensions were vortexed at 60 °C, then extruded through two, stacked 0.1 μ m
polycarbonate membranes 10 times at 40 psig and 60 °C to yield ammonium besylate liposomes (ABLs)
with a particle size (determined by dynamic light scattering) of 99.5 ±  3.5 nm and a polydispersity index
of 0.13 ±  0.08 nm. Active loading of TPT into ABLs was performed by generating a low intravesicular
pH via an ammonia gradient7. Extravesicular ammonia was removed to establish the gradient by passing
0.6 mL of ABLs through a Sephadex G-25 size exclusion column pre-equilibrated with pH 5.5 100 mM
2-(N-morpholino)ethanesulfonic acid (MES) buffer. The first 2.5 mL fraction eluted from the column
was discarded. The next 2.5 mL containing ABLs suspended in MES buffer was collected and 1.5 mL of
the eluted suspension was mixed with an equal volume of TPT dissolved in the same pH 5.5 MES buffer
to achieve a total extravesicular TPT concentration of 100 μ M and a lipid concentration of 1.86 mg/
mL. TPT active loading was performed for 1 hour at 60 °C with this suspension and achieved a loading
efficiency of 72%. The resulting LTPT formulation was used for release studies after passing through a
Sephadex-G25 column equilibrated with pH 7.4 phosphate buffer saline (PBS) or stored at 4 °C until
needed.

®

®

Liposomal Characterization. Liposome particle size was analyzed by dynamic light scattering with

™

the aid of a Beckman Delsa Nano C Particle Sizer (Brea, CA) as reported previously72. TPT suspensions
collected during active loading or release studies were diluted with acidified methanol (0.001 N HCl) and
stored at − 20 °C until analyses. Acidification converts TPT to its lactone form, which was later analyzed
by HPLC72. Active drug loading and lipid composition of the liposomal formulations were determined
as previously described74,75. Briefly, TPT lactone concentration was determined by HPLC using a Waters
Symmetry C18 column (4.6 ×  150 mm, 5 μ m) and a mobile phase (16% acetonitrile:84% (v/v) of 5% (pH
5.5) triethylamine acetate buffer) at a flow rate of 1 mL/min. A fluorescence detector (M474) operating
at excitation and emission wavelengths of 380 and 560 nm was used to monitor the lactone form of
TPT, which exhibited a retention time of 4 min. A linear response was observed for TPT standards over
the concentration range of 20–200 nM in acidified methanol. For lipid content determination, aliquots
of liposome suspensions (100 – 250 μ L) were dried at room temperature under N2, then dissolved in
chilled solvent (80% chloroform:19.5% methanol:0.5%(v/v) NH4OH). Lipid samples were analyzed using
a Waters Alliance 2695 separation module and an Allsphere (Alltech Associates, Inc., Deerfield, IL) silica
column (4 ×  150 mm, 5 μ m) and guard column (20 ×  4.0 mm, 5 μ m) and a mobile phase (80% methanol:19.5% water:0.5% (v/v) NH4OH) at a flow rate of 1 mL/min. DSPC was quantified with this HPLC
method using an evaporative light scattering detector (ELSD, Sedere, Inc., Lawrenceville, NJ) operated
at 40 psig and 40 °C. DSPC standards (0.05 – 0.3 mg/mL) were dissolved in the same solvent as liposome
samples. Plots of the logarithms of standard peak areas versus the logarithms of concentration were linear
over this concentration range.

In-vitro release kinetics of liposomal TPT in PBS or culture medium at pH 7.4.

A previously
developed fluorescence method capable of determining the release kinetics of LTPT in PBS and plasma
was used to monitor LTPT release in PBS and cell culture media in this study24. Briefly, 0.5 mL of LTPT
suspension was passed through a Sephadex G-25 column equilibrated with PBS or cell culture medium
to remove unentrapped TPT resulting in suspensions of TPT-loaded liposomes in the release media of
interest. The first 2.5 mL eluted from the column was discarded and the next 2.5 mL containing LTPT
was collected and diluted four fold with PBS or cell culture medium. TPT release was monitored at 37 °C

®
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using the red shift in TPT’s fluorescence excitation spectra that occurs as it is released72. Excitation spectra (290–500 nm) were collected at an emission wavelength of 550 nm using a FluoroMax-3, Jobin Yvon
Inc (Edison, NJ) operated at 37 °C, 0.5 s integration time, and 1.5 nm slit width. Free TPT concentration
was determined by comparing the fluorescence intensity (excitation of 410 nm) of samples to TPT standards (0.2 μ M–5 μ M) in PBS or culture medium as described previously76. A 100 μ L aliquot of liposomal
suspension was also dissolved in acidified Me OH and analyzed by HPLC to determine the total TPT
suspension concentration at the beginning of each release study.

Cell lines and Culture.

4T1 is a highly metastatic murine mammary epithelial cell line, representative of the human triple negative breast cancer phenotype that does not express estrogen, progesterone
and Her2 receptor77. Both 4T1 and green fluorescent protein expressing 4T1 (GFP-4T1) cell lines are
used in this study. The 2H11 cell line validated as a tumor-like endothelial cell line by Walter-Yohrling
et al.65 has attributes of both normal endothelial cells28 as well as endothelial cells directly isolated
from tumors78. Tumor and endothelial cells were cultured in high-glucose Dulbecco’s modified Eagle’s
medium supplemented with 5% fetal bovine serum, sodium pyruvate, non-essential amino acids, and 1%
penicillin-streptomycin (Invitrogen, Carlsbad, CA) at 37 °C in a humidified atmosphere with 5% CO2.

X-Ray Irradiation. High energy radiation (X-Ray) exposure was given using the Varian TrueBeam
System (Palo Alto, CA) at the Department of Radiation Medicine at the University of Kentucky. The
instrument was set at a radiation dose rate of 1.018 ±  0.10 Gy/min at 150 kV and 6.6 mA. The standard
radiation dose in all experiments was 3 Gy.
MTT assay.

Cells were seeded at a density of 2 ×  103 cells/well in 96-well plates and incubated at 37 °C
for 24 hours. Cells were treated with nine different concentrations of TPT (0.075–5 μ M) with and without radiation exposure. The radiation was applied 6 hours after TPT treatment. Seventy-two hours later,
50 μ L of MTT (5 mg/mL in PBS) was added to each well and incubated at 37 °C for 4 hours followed by
dimethylsulfoxide (DMSO) solubilization of the cells. The dissolved chromogen in DMSO was measured
at an absorbance wavelength of 540 nm using a Spectramax microplate reader (Molecular Devices LLC,
Sunnyvale, CA) at 37 °C. The percentage of viable cells was determined by comparison with untreated
controls. The median inhibitory concentration or IC50 (i.e., 50% reduction in cell viability) was determined for both tumor and endothelial cell lines.

Clonogenic assay.

One to five hundred cells were plated in 6-well culture plates and then treated
with 1/2 and 1/4 the IC50 dose of TPT in triplicate. Cells were irradiated with 3 Gy of radiation 6 hours
after drug treatment. After radiation exposure, plates were incubated at 37 °C and 5% CO2 for 10–12
days until large colonies (> 1 mm) formed. The colonies were fixed and stained with 0.5% crystal violet
(Sigma Aldrich, St. Louis, MO) in 50% methanol/water. Colonies were counted using ImageJ software
and confirmed by manual counting.
Plating efficiency (PE) and survival fraction (SF) were calculated using following equations79:

PE =

number of colonies formed
number of colonies in treatment group
× 100%; SF =
number of cells seeded
number of cells seeded × PE

Survival fraction was determined for both tumor and endothelial cell lines after TPT treatment either
in conjunction with or without radiation exposure. Survival fractions were calculated from n =  3 samples
for each experiment.

3D “Hanging drop” co-cultures. Tumor-endothelial cell spheroids (TES) were generated by

co-culturing 4T1 tumor cells and 2H11 endothelial cells in “hanging drops” of medium (Dulbecco modified Eagle medium with 10% fetal bovine serum and antibiotic mix) as previously described28. A single
cell suspension of 4T1 cells and 2H11 cells (3000 cells/20 μ L) was dispensed on the inside of the lid of
each well of a 48-well cell culture plate, Greiner CellStar (Kaysville, UT). Spheroids were grown as hanging drops for 10 days and transferred to Greiner repellent plates when required for assessing treatment
response. Spheroids composed of only GFP-4T1 cells were made with the same protocol.

Toxicity evaluation of Liposomal TPT in TES.

Randomly selected equal-sized TES were treated
with free TPT or the nanoliposomal suspension (LTPT). The selected drug treatment groups were irradiated at 3 Gy after 6 hours. Drug containing media was replaced after 24 hours. Images for representation
and quantitation of cell death, fluorescence and structural changes in the TES were obtained at day 10
using an Olympus FV1000 laser scanning confocal microscope (Olympus America Inc. Melville, NY)
and a Typhoon FLA 7000 (GE Healthcare, Piscataway, NJ). TES from all treatment groups were imaged
for green fluorescent protein (GFP) in 4T1 cells and stained for propidium iodide (PI) to quantify the
abundance of dead cells.

Scanning electron microscopy. 4T1 tumor cell and 4T1-2H11 tumor-endothelial cell spheroids
grown in hanging drops for 10 days were transferred to Formvar/Carbon grids (Ted Pella Inc, Redding,
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CA). The spheroid containing grids were imaged with an S-3200-N Hitachi scanning electron microscope at an accelerating voltage of 16 kV to observe the spheroid compactness or integrity and extracellular matrix formation.

Immunohistochemistry.

®

Spheroids were harvested and frozen in Tissue-Tek O.C.T., (Miles USA,
Inc. Elkhart, IN). Eight μ m cryostat sections were obtained with a Leica CM1950 cryotome and transferred on to Superfrost Plus slides (Fischer Scientific, Boston, MA) for immunostaining. Slides were
incubated in polyclonal rabbit anti-human fibronectin (Q0149, Dako) and collagen Type IV mouse monoclonal antibodies for 30 min at room temperature followed by labelling using a Dako Envision +  kit
(IR630) from Dako North America Inc. (Carpinteria, CA) according to the manufacturer’s instructions.
Signal was visualized with 3,3′ -Diaminobenzidine (DAB) followed by a light hematoxylin counterstain.
Images were taken at 40X magnification using a Nikon Ti E upright microscope with a Cool SNAP HQ2
CCD camera (Tokyo, Japan) and processed with NIS-Elements basic research software.

™

Hematoxylin and Eosin Staining and Imaging. Hematoxylin and eosin (H&E) staining was performed by staining the cryostat sections of TES with Harris hematoxylin (aluminum potassium sulfate,
hematoxylin, absolute alcohol, mercuric oxide, and glacial acetic acid) followed by 1% acid alcohol and,
subsequently, 1% eosin. Images of spheroids were obtained as described above.
Microscopy and image analyses. TES fluorescence images were captured using a Olympus FV1000

laser scanning confocal microscope (Olympus America Inc. Melville, NY) equipped with 10X and 20X
objectives (NA =  1.32). Two channels were acquired sequentially with the following excitation and emission parameters: 405 and 465–500 nm for accumulation of TPT or GFP expression in tumor cells and
543 and 555–615 nm for PI staining of dead cells. The monochromatic differential interference contrast
(DIC) images provided assessment of TES morphology and size. Gains were adjusted to avoid saturation
in pixel intensity. Each TES image consisted of 24 optical images separated by 5 μ m along the z-axis captured at a 512 ×  512 resolution and a speed of 10 μ s/pixel for both channels. A DIC image was acquired
after each Z-stack image for accurate sizing. All 24 optical slices were collapsed to generate a maximum
(i.e. cumulative) intensity projection image with the FV10-ASW 1.7 image processing software. TPT/
GFP or PI staining was quantified using an Olympus image analysis or ImageJ 1.47v (NIH, Bethesda,
USA) software.

Phospho MAPK Antibody Array.

TES harvested 10 days post-treatment were homogenized using a
21-gauge syringe in lysis buffer as described earlier28. Insoluble material were removed by centrifugation
(15 min, 12000 g). The protein concentration was determined using micro BCA protein assay kit (Thermo
scientific Pierce, Rockford, IL). 125 μ g of lysate was hybridized to a human phospho MAPK antibody
array (R&D Systems Inc, Minneapolis, MN) as instructed.

Pathway Analysis. The Ingenuity Pathway Analysis Tool was used to identify gene networks and
examine the functional associations between differentially expressed proteins in the MAPK arrays
obtained from incubation with lysates of TES following treatment (www.ingenuity.com).
Statistical analyses. Data are expressed as mean ±  SD of at least three different experiments unless

otherwise mentioned. Cell survival, sizing, and PI/GFP data for TES were represented as means (N =  4–12
TES per group) ±  SD. Statistical analyses were performed using Graphpad Prism software version 5.04
(GraphPad.com). Two tailed unpaired t-tests with Welch’s correction was used to determine statistical
significance. The level of significance was accepted at p <  0.05. For analysis of data from the Phospho
MAPK antibody arrays, K-means clustering in conjunction with correlation metric was used to partition
the markers into two clusters based on their expression profile across the three conditions corresponding
to the following treatments: radiation (3 Gy), 3 Gy +  TPT and 3 Gy +  LTPT.
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